Insights into Melanoma Clinical Practice: A Perspective for Future Research

Author:

Lam Giang T.1,Martini Carmela1ORCID,Brooks Tiffany23,Prabhakaran Sarita4ORCID,Hopkins Ashley M.4ORCID,Ung Ben S.-Y.1ORCID,Tang Jingying1,Caruso Maria C.1ORCID,Brooks Robert D.1ORCID,Johnson Ian R. D.1ORCID,Sorvina Alexandra1ORCID,Hickey Shane M.1ORCID,Karageorgos Litsa1ORCID,Klebe Sonja45ORCID,O’Leary John J.6,Brooks Douglas A.16ORCID,Logan Jessica M.1ORCID

Affiliation:

1. Clinical and Health Sciences, University of South Australia, North Terrace, Adelaide, SA 5000, Australia

2. Adelaide Medical School, University of Adelaide, North Terrace, Adelaide, SA 5000, Australia

3. Aware Women’s Health Private Clinic, Adelaide, SA 5006, Australia

4. College of Medicine and Public Health, Flinders University, Adelaide, SA 5042, Australia

5. Department of Surgical Pathology, SA Pathology at Flinders Medical Centre, Adelaide, SA 5042, Australia

6. Department of Histopathology, Trinity College Dublin, D02 PN40 Dublin, Ireland

Abstract

Background: Early diagnosis is the key to improving outcomes for patients with melanoma, and this requires a standardized histological assessment approach. The objective of this survey was to understand the challenges faced by clinicians when assessing melanoma cases, and to provide a perspective for future studies. Methods: Between April 2022 and February 2023, national and international dermatologists, pathologists, general practitioners, and laboratory managers were invited to participate in a six-question online survey. The data from the survey were assessed using descriptive statistics and qualitative responses. Results: A total of 54 responses were received, with a 51.4% (n = 28) full completion rate. Of the respondents, 96.4% reported ambiguity in their monthly melanoma diagnosis, and 82.1% routinely requested immunohistochemistry (IHC) testing to confirm diagnosis. SOX10 was the most frequently requested marker, and most respondents preferred multiple markers over a single marker. Diagnostic and prognostic tests, as well as therapeutic options and patient management, were all identified as important areas for future research. Conclusions: The respondents indicated that the use of multiple IHC markers is essential to facilitate diagnostic accuracy in melanoma assessment. Survey responses indicate there is an urgent need to develop new biomarkers for clinical decision making at multiple critical intervention points.

Funder

Rattigan Family Trust

University of South Australia

National Health and Medical Research Council, Australia

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference42 articles.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3